Author(s)

Bambara Augustin Tozoula^1,2*, Ouedraogo Nina-Astrid^3,4, Atenguena Okobalemba Etienne⁵, Kabore Bernard², Akanni Fayçal², Sama Alice Cynthia², Ousseini Diallo^3,6

¹Laboratory of Non-Communicable Diseases, Training and Research Unit in Health Sciences, Joseph Ki Zerbo University, Ouagadougou, Burkina Faso.
²Department of Cancerology, Yalgado Ouédraogo University Hospital, Ouagadougou, Burkina Faso.
³Laboratory of Radiodiagnosis and Medical Imaging, Training and Research Unit in Health Sciences, Joseph Ki Zerbo University, Ouagadougou, Burkina Faso.
⁴Medical Imaging Department, Bogodogo University Hospital, Ouagadougou, Burkina Faso.
⁵Faculty of Medicine and Biomedical Sciences, University of Yaoundé I, Yaoundé, Cameroon.
⁶Medical Imaging Department of Yalgado Ouédraogo University Hospital, Ouagadougou, Burkina Faso.

Background: Neoadjuvant chemotherapy (NAC) is one of the treatment options for breast cancer. Its aim is to significantly reduce the size of the tumour in preparation for surgery. The aim of this work is to analyze the conditions of clinical and radiological evaluation of NAC at the Yalgado Ouédraogo University Hospital (CHUYO). Patients and Methods: This was a descriptive cross-sectional study based on the medical records of patients followed up in the cancer department of the CHUYO from 1 January 2013 to 31 December 2021. All patients followed for histologically proven, non-metastatic breast cancer and having received at least one course of NAC were included in this study. The variables were related to the socio-demographic characteristics of the patients, the indications, the protocols of NAC and the sequences of evaluation of the tumour response (clinical, radiological and anatomopathological). Results: We collected 105 cases. The average age of the patients concerned was 44 years. The most frequent histological type was non-specific invasive carcinoma in 97.1% of cases. Immunohistochemically, triple-negative patients accounted for 51.4%. At the initial stage, all patients underwent clinical exploration. Clinical measurement of the tumour was performed in 70.5% of cases. The radiological size of the tumour was determined by ultrasound in 59.1% of cases. One patient had a breast MRI. Thirty-one patients were lost to follow-up after the initial evaluation. At mid-term and at the end of treatment, clinical tumour size was performed in 38.6% and 45.6% of cases respectively. There was no breast imaging performed at mid- and end-of-treatment. CT scans were performed in all cases at baseline, mid-term and end of treatment for extension assessment but did not mention the breast tumour. The tumour response rate was not recorded. Conclusion: Clinical assessment of tumour response is almost always empirical and not quantified. Medical imaging examinations are prescribed sparingly so as not to compromise the regularity of treatment and patient assessment.

Tumour Response, Neoadjuvant Chemotherapy, Breast Imaging, Burkina Faso

Tozoula, B. , Nina-Astrid, O. , Etienne, A. , Bernard, K. , Fayçal, A. , Cynthia, S. and Diallo, O. (2022) Evaluation of Clinical and Radiological Tumour Response during Neo-Adjuvant Breast Cancer Chemotherapy at Yalgado Ouedraogo University Hospital. Advances in Breast Cancer Research, 11, 183-194. doi: 10.4236/abcr.2022.114015.